Possible Offer

Advanced Medical Solutions Group plc

(“AMS” or the “Company”)

Statement re. Possible Offer

The Board of Advanced Medical Solutions Group plc notes the recent announcement by Consort Medical Plc (“Consort”) confirming that it has made an approach for AMS which may or may not lead to an offer being made for AMS.  

The Board of AMS can confirm that it did receive an approach with a subsequent verbal indication of a possible price to be offered.  The Board of AMS and Investec confirm that they firmly rejected this approach. Since rejecting this verbal indication the Board of AMS has not received a revised approach nor to date has it received any formal written offer from Consort.

The Board of AMS advises shareholders to take no action at this stage. Further announcements will be made as appropriate.

Enquiries:

Pursuant to Rule 2.10 of the City Code on Mergers and Acquisitions (the “Code”), AMS confirms that it has 145,016,366 ordinary shares of 5p each (“Ordinary Shares”), in issue and admitted to trading on the AIM market of the London Stock Exchange.

Dealing Disclosure Requirements

Dealing Disclosure Requirements under the provisions of Rule 8.3 of the Code, require that if any person is, or becomes, “interested” (directly or indirectly) in 1% or more of any class of “relevant securities” of AMS, all “dealings” in any “relevant securities” of that company (including by means of an option in respect of, or a derivative referenced to, any such “relevant securities”), it must be publicly disclosed by no later than 3.30p.m. (London time) on the London business day following the date of the relevant transaction.

This requirement will continue until the date on which the offer becomes, or is declared, unconditional to acquire an “interest” in “relevant securities” of AMS, they will be deemed to be a single person for the purpose of Rule 8.3. Under the provisions of Rule 8.1 of the Code, all “dealings” in “relevant securities” of AMS by a potential offeror or by AMS, or by any of their respective “associates”, must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose “relevant securities” “dealings” should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel’s website at www.thetakeoverpanel.org.uk. “Interests in securities” arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an “interest” by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative reference to, securities. Terms in quotation marks are defined in the Code, which can also be found on the Panel’s website. If you are in any doubt as to whether or not you are required to disclose a “dealing” under Rule 8, you should consult the Panel.

Rule 19.11 disclosure

In accordance with Rule 19.11 of the Code, a copy of this Announcement will be published on the AMS website: www.admedsol.com.